Literature DB >> 21723355

An alternative renewable source of squalene for use in emulsion adjuvants.

Luis A Brito1, Michelle Chan, Barbara Baudner, Simona Gallorini, George Santos, Derek T O'Hagan, Manmohan Singh.   

Abstract

Emulsions have been used to boost immunogenicity of antigens since the discovery of complete Freunds adjuvant. Optimization to reduce reactogenicity of emulsion adjuvants lead to the development of oil in water emulsions based on squalene. MF59 is an oil-in-water emulsion that is a component of an approved influenza product in Europe. Currently MF59 is manufactured from squalene derived from an animal source. Recently a high purity plant-derived squalene source has become available at an appropriate purity for a vaccine adjuvant. The purpose of this study was to evaluate and compare animal-derived squalene and plant-derived squalene for equivalency. Nanoemulsions were prepared and analyzed for size and viscosity prepared from each source. The two emulsions were administered in two separate animal studies, one focusing on Neisseria meningitidis B, and one focusing on influenza. Readouts were ELISA titers for each antigen and serum bactericidal activity for N. meningitidis B, and hemagglutinin inhibition for influenza to see the functionality of the antibodies produced. Results indicate that there are no differences between the antibodies elicited after immunization from an emulsion made with oil derived from either an animal or plant-source.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723355     DOI: 10.1016/j.vaccine.2011.06.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  Vaccine       Date:  2011-09-09       Impact factor: 3.641

2.  Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.

Authors:  Christopher B Fox; Susan L Baldwin; Malcolm S Duthie; Steven G Reed; Thomas S Vedvick
Journal:  AAPS PharmSciTech       Date:  2012-03-14       Impact factor: 3.246

Review 3.  Fungal cell wall vaccines: an update.

Authors:  John E Edwards
Journal:  J Med Microbiol       Date:  2012-01-19       Impact factor: 2.472

4.  Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice.

Authors:  Armin Hekele; Sylvie Bertholet; Jacob Archer; Daniel G Gibson; Giuseppe Palladino; Luis A Brito; Gillis R Otten; Michela Brazzoli; Scilla Buccato; Alessandra Bonci; Daniele Casini; Domenico Maione; Zhi-Qing Qi; John E Gill; Nicky C Caiazza; Jun Urano; Bolyn Hubby; George F Gao; Yuelong Shu; Ennio De Gregorio; Christian W Mandl; Peter W Mason; Ethan C Settembre; Jeffrey B Ulmer; J Craig Venter; Philip R Dormitzer; Rino Rappuoli; Andrew J Geall
Journal:  Emerg Microbes Infect       Date:  2013-08-14       Impact factor: 7.163

Review 5.  Prospects on the Use of Schizochytrium sp. to Develop Oral Vaccines.

Authors:  Abel Ramos-Vega; Sergio Rosales-Mendoza; Bernardo Bañuelos-Hernández; Carlos Angulo
Journal:  Front Microbiol       Date:  2018-10-25       Impact factor: 5.640

6.  MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice.

Authors:  Ming Yang; Youyou Yan; Mingli Fang; Min Wan; Xiuli Wu; Xiaoling Zhang; Tiesuo Zhao; Hongfei Wei; Dandan Song; Liying Wang; Yongli Yu
Journal:  Int Immunopharmacol       Date:  2012-05-14       Impact factor: 4.932

Review 7.  "World in motion" - emulsion adjuvants rising to meet the pandemic challenges.

Authors:  Derek T O'Hagan; Robbert van der Most; Rushit N Lodaya; Margherita Coccia; Giuseppe Lofano
Journal:  NPJ Vaccines       Date:  2021-12-21       Impact factor: 7.344

8.  Synthetic Biology-derived triterpenes as efficacious immunomodulating adjuvants.

Authors:  Mizuki Tateno; Barbara J Stone; Sarah J Srodulski; Stephanie Reedy; Thomas R Gawriluk; Thomas M Chambers; Jerold Woodward; Joe Chappell; Chase F Kempinski
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

9.  Squalene Emulsion Manufacturing Process Scale-Up for Enhanced Global Pandemic Response.

Authors:  Tony Phan; Christian Devine; Erik D Laursen; Adrian Simpson; Aaron Kahn; Amit P Khandhar; Steven Mesite; Brad Besse; Ken J Mabery; Elizabeth I Flanagan; Christopher B Fox
Journal:  Pharmaceuticals (Basel)       Date:  2020-07-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.